Acuta Capital Partners’s Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 ONSIW Stock Holding History

Acuta Capital Partners’s Portfolio ONSIW Stock Details ONSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-96,833	Closed	-$12K	–	95
2017 Q3	$12K	Hold	96,833	–	–	﹤0.01%	63
2017 Q2	$17K	Hold	96,833	–	–	﹤0.01%	59
2017 Q1	$77K	Hold	96,833	–	–	0.02%	66
2016 Q4	$18K	Hold	96,833	–	–	0.01%	49
2016 Q3	$47K	Hold	96,833	–	–	0.02%	65
2016 Q2	$45K	Buy	+96,833	New	+$37.1K	0.02%	63

Other funds holding ONSIW

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Acuta Capital Partners's ONSIW Position: Q4 2017 in Review

Acuta Capital Partners sold out of Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 (ONSIW) in Q4 2017, closing a stake of 96,833 shares — an estimated $12K sold.

Acuta Capital Partners first reported a position in ONSIW in Q2 2016 and held it in 6 quarters. The position peaked at $77K in Q1 2017. 5 funds tracked by Wall St. Rank hold ONSIW as of Q4 2017.

Acuta Capital Partners reported no remaining Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 position as of Q4 2017 after selling out during the quarter.
Acuta Capital Partners sold 96,833 Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 shares in Q4 2017, an estimated $12K.
Acuta Capital Partners first reported a position in Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 in Q2 2016 and held it in 6 quarters.
Acuta Capital Partners's Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 position peaked at $77K in Q1 2017.
5 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 as of Q4 2017.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.